2. Immunology/Inflammation
  3. CD47
  4. ZL-1201

ZL-1201 是一种重组人源化抗 CD47 IgG4 抗体。ZL-1201 干扰 CD47-SIRPα 相互作用。ZL-1201 调节肿瘤微环境。ZL-1201 促进肿瘤相关巨噬细胞的吞噬活性。ZL-1201 显著增强 M2 巨噬细胞的吞噬作用，但对 M1 巨噬细胞无此作用。ZL-1201 与单克隆抗体和化疗联合使用，在多种实体瘤模型中实现最大的抗肿瘤效果。ZL-1201 可用于淋巴瘤、乳腺癌、卵巢癌、头颈部鳞状细胞癌和胃癌的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

ZL-1201

ZL-1201 Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
1 mg   询价  
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

ZL-1201 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer[1].

反应种属

Human
IC50 & Target

CD47
体外研究
(In Vitro)

ZL-1201 (15 min) 与 Jurkat 细胞上的 CD47 结合[1]。
ZL-1201 (10 μg/mL；30 min) 与 Trastuzumab (HY-P9907)、Cetuximab (HY-P9905) 或 Rituximab (HY-P9913) 联用时，与单试剂或同型对照相比，可显著提高吞噬指数[1]。
ZL-1201 (2 h) 不会在全血中诱导血凝反应[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ZL-1201 相关抗体:
体内研究
(In Vivo)

ZL-1201 (10 mg/kg；i.p.；每周两次；3–12 周) 可增强其对荷淋巴瘤、乳腺癌、卵巢癌、头颈部鳞状细胞癌及胃癌异种移植瘤 BALB/c 裸鼠的抗肿瘤功效 (在 Raji 淋巴瘤异种移植瘤中 TGI＞80%)[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude mice[1]
Dosage: 10 mg/kg
Administration: i.p.; twice per week; 3–12 weeks
Result: Achieved >80% tumor growth inhibition (TGI) in Raji lymphoma xenografts; showed limited TGI (<50%) alone in solid tumor xenografts; significantly inhibited tumor growth when combined with therapeutic mAbs and chemotherapy, with triple combinations achieving maximal antitumor efficacy; increased intratumoral M1 macrophages, decreased M2 macrophages, and modulated cytokine release (increased TNFα/MCSF, decreased IL4) in the SKOV3 model
基因 ID

961  [NCBI]

Accession
应用

ELISA, FACS, Functional assay
偶联物

Unconjugated
复溶方法

The product can be reconstituted/diluted with sterile PBS or saline.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

ZL-1201 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ZL-1201ZL1201ZL 1201CD47Cluster of Differentiation 47MER6OA3CD47-SIRPα interactionM2 macrophagemonocyte-derived macrophagesSIRPαxenograft studiestumor modelsantitumor immunityJurkat cellstumor microenvironmentInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
ZL-1201
目录号：
HY-P991927
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z